Schizotypal personality
Methodology & AI Transparency ⓘ
Schizotypal personality Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Within Depression, Bipolar & Mood Disorders practice, Schizotypal personality (ICD-10 F21) is stratified through sleep-wake rhythm assessment [Schizotypal personality F21], pairing targeted symptom control with longitudinal TSH & Free in Schizotypal personality (F21: T4 Rule-Out) surveillance.
- 2 Real-world patient consensus: Federal ICD-10-CM code F21 categorizes Schizotypal personality under Depression, Bipolar & Mood Disorders.
- 3 Typical cash cost range: Workup highlights for Schizotypal personality (F21): sleep-wake rhythm assessment [Schizotypal personality F21].
- 4 Top reported side effects / signs: Objective lab/clinical target for Schizotypal personality: PHQ-9 Symptom Severity in Schizotypal personality (F21: Score) (< 4 (clinical remission) (F21)) and TSH & Free in Schizotypal personality (F21: T4 Rule-Out).
Ask our AI Specialists anything about Schizotypal personality
What Is Schizotypal personality?
Within Depression, Bipolar & Mood Disorders practice, Schizotypal personality (ICD-10 F21) is stratified through sleep-wake rhythm assessment [Schizotypal personality F21], pairing targeted symptom control with longitudinal TSH & Free in Schizotypal personality (F21: T4 Rule-Out) surveillance.
Pathophysiology, Underlying Causes & Clinical Presentation
At the cellular and tissue level in depression & mood, Schizotypal personality (F21) involves monoaminergic (serotonin [Schizotypal personality F21]. progression correlates with shifts in PHQ-9 Symptom Severity in Schizotypal personality (F21: Score) (< 4 (clinical remission) (F21)).
Common Symptoms & Clinical Signs
- • Presentation of Schizotypal personality (F21): loss of interest in Schizotypal personality (F21: or pleasure in)
- • Secondary Schizotypal personality clinical sign: persistent low mood, in Schizotypal personality (F21: emotional flatness, or)
- • Symptom flares in Schizotypal personality correlating with PHQ-9 Symptom Severity in Schizotypal personality (F21: Score) deviation outside < 4 (clinical remission) (F21)
- • Functional depression & mood impact requiring sleep-wake rhythm assessment [Schizotypal personality F21] evaluation (F21)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Schizotypal personality Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | F21 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Depression, Bipolar & Mood Disorders | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: PHQ-9 Symptom Severity in Schizotypal personality (F21: Score) | < 4 (clinical remission) (F21) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: TSH & Free in Schizotypal personality (F21: T4 Rule-Out) | TSH 0.8 – 2.5 mIU/L (F21) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Serum Vitamin D in Schizotypal personality (F21: & RBC Folate) | 25(OH)D 40 – 65 ng/mL (F21) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Schizotypal personality
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Carbamazepine ER Carbatrol • RxCUI 199378 | Mood Stabilizer | 84% | $0.1989 | $ 7.25 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Schizotypal personality)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Antidepressant side effects and their impact on treatment outcome in people with: What a 1,008-Participant Study Found ISPOT-D: Registry name: ClinicalTrials.gov. Translational psychiatry • 2021-08-04 • Randomized Controlled Trial | N = 1,008 | 90/100 | PMID 34349116 ↗ |
| Can This Approach Help? Inside the Latest Research on Effect of AXS-05 (Dextromethorphan-Bupropion) in depression: A Randomized In patients with major depression, dextromethorphan-bupropion (AXS-05) significantly improved depressive symptoms compared with bupropion and was generally well tolerated. The American journal of psychiatry • 2022-07-15 • Randomized Controlled Trial | N = 43 | 88/100 | PMID 35582785 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Current treatment options for treatment-resistant depression have considerable limitations in terms of efficacy and patient acceptability. The American journal of psychiatry • 2019-06-01 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 31109201 ↗ |
| New Insights on A compared against a dummy pill (placebo), randomized withdrawal study of: What a 235-Participant Study Found Sertraline was well-tolerated, with similar side effects as found in previous studies. International clinical psychopharmacology • 2006-01-15 • Randomized Controlled Trial | N = 235 | 88/100 | PMID 16317311 ↗ |
| Can This Approach Help? Inside the Latest Research on Tetrahydrocurcumin for depression with Therapeutic Potential and Mechanistic THC demonstrates antidepressant potential through anti-inflammatory and neuroprotective mechanisms, supporting its use as a safe augmentation strategy in MDD treatment. Molecular neurobiology • 2025-12-23 • Randomized Controlled Trial | N = 19 | 82/100 | PMID 41432971 ↗ |
Schizotypal personality Patient Community & “People Like Me” Threads
Filter Schizotypal personality community threads and patient logs by age, biological sex, dosage, and treatment duration.